Plus therapeutics to present at the society for neurooncology annual meeting and will host key opinion leader webinar

Update on the respect-gbm trial, including phase 2, with rhenium-186 obisbemeda in recurrent glioblastoma will be presented at sno annual meeting update on the respect-gbm trial, including phase 2, with rhenium-186 obisbemeda in recurrent glioblastoma will be presented at sno annual meeting
pstv Ratings Summary
pstv Quant Ranking